Serum Institute of India (SII), the world’s largest vaccine manufacturer, has announced the acquisition of a 20% stake in IntegriMedical, a company specializing in innovative drug delivery systems. This strategic investment aims to advance the development and distribution of IntegriMedical’s needle-free injection system (N-FIS), a cutting-edge technology that promises to revolutionize the administration of vaccines and other biologics.

IntegriMedical’s N-FIS uses a high-velocity jet stream powered by mechanical means to deliver medications effectively and consistently, eliminating the need for traditional needles. This US-patented technology has received regulatory approvals from the Central Drugs Standard Control Organisation (CDSCO) in India, the CE mark for European regulatory compliance, and the Medical Device Single Audit Program (MDSAP) certification in Australia. Additionally, it is ISO 13485 certified, indicating compliance with international standards for medical devices.

Adar Poonawalla, CEO of SII, expressed excitement about the collaboration, stating, “IntegriMedical’s N-FIS represents a significant advancement in drug delivery, and we envision a needle-free solution to deliver vaccines. We believe this could potentially revolutionize the way we administer vaccines, making the process more comfortable for patients and healthcare professionals.”

The needle-free injection system offers several advantages over traditional needle-based methods. It addresses needle phobia, a common concern among patients, by providing a painless alternative. It also enhances safety by preventing needle-stick injuries and cross-contamination, which are significant risks in clinical settings. Furthermore, the convenience of the needle-free system can streamline the vaccination process, making it easier for healthcare providers to administer vaccines efficiently.

Sarvesh Mutha, Managing Director of IntegriMedical, highlighted the importance of SII’s investment, stating, “This investment is a testament to the potential of our needle-free Injection System technology and its ability to revolutionize drug delivery. SII’s expertise in vaccine manufacturing and global distribution will be invaluable as we work towards making our technology more widely accessible to patients worldwide.”

The N-FIS technology will soon be available in the Indian private market, offering a new option for patients and healthcare providers. With SII’s backing, IntegriMedical aims to expand the reach of this innovative technology, ensuring that more people can benefit from needle-free injections. Serum Institute of India is also the manufacturer of CoviShield vaccine in India.